#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3074	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2282	387.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1592	1592	C	424	C	382	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5338	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4126	387.4	0	.	n	.	0	T695C	SNP	695	695	T	1275	1275	C	376	C,G,A,T	333,2,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5338	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4126	387.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1917	1917	A	492	A	449	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5338	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4126	387.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2551	2551	C	497	C	462	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5338	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4126	387.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3177	3177	T	499	T,A	439,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5338	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4126	387.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2625	2625	A	531	A	483	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	830	folP	852	852	100.0	folP.l15.c4.ctg.1	1886	130.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1198	1200	AGC	155;155;156	A;G;C,T	143;145;142,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1482	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3831	115.9	1	SNP	p	S91F	0	.	.	271	273	TCC	773	775	TCC	121;121;121	T;C;C	106;110;109	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1482	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3831	115.9	1	SNP	p	D95G	0	.	.	283	285	GAC	785	787	GAC	120;120;120	G;A,C;C,A	109;106,2;108,2	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1482	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3831	115.9	1	SNP	p	D95N	0	.	.	283	285	GAC	785	787	GAC	120;120;120	G;A,C;C,A	109;106,2;108,2	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	748	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1915	117.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	504	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1449	104.2	0	.	n	.	0	C187G	SNP	187	187	C	803	803	G	174	G	164	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1562	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3373	138.5	1	SNP	p	D86N	0	.	.	256	258	GAC	771	773	GAC	167;167;166	G;A;C	138;136;142	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1562	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3373	138.5	1	SNP	p	S87R	0	.	.	259	261	AGT	774	776	AGT	166;166;167	A,C;G,C;T	138,1;143,1;142	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1562	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3373	138.5	1	SNP	p	S87W	0	.	.	259	261	AGT	774	776	AGT	166;166;167	A,C;G,C;T	138,1;143,1;142	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1562	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3373	138.5	1	SNP	p	S87I	0	.	.	259	261	AGT	774	776	AGT	166;166;167	A,C;G,C;T	138,1;143,1;142	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1562	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3373	138.5	1	SNP	p	S88P	0	.	.	262	264	TCC	777	779	TCC	168;167;168	T;C;C	144;144;148	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1554	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3337	139.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1963	1965	GGC	184;182;181	G;G;C,T	166;163;160,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2834	109.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1529	1531	GCA	171;172;171	G;C,T;A,C	144;155,1;151,2	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2834	109.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1532	1534	ATC	171;170;171	A;T,A;C,A,G	156;151,1;151,2,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2834	109.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1544	1546	GTG	174;175;176	G,A,C;T,C,G;G,C	152,1,1;149,1,1;151,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2834	109.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1544	1546	GTG	174;175;176	G,A,C;T,C,G;G,C	152,1,1;149,1,1;151,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2834	109.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2048	2050	ACC	121;121;121	A;C;C	108;109;109	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2834	109.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2102	2104	GCG	120;120;121	G;C,G;G	103;91,1;94	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2834	109.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2102	2104	GCG	120;120;121	G;C,G;G	103;91,1;94	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2834	109.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2225	2227	GGC	128;129;130	G;G;C	116;119;118	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2834	109.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2234	2236	GGC	134;133;132	G;G;C	116;117;123	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2834	109.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2252	2254	CCG	131;131;132	C;C;G	115;118;114	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1196	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3498	102.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	760	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2420	94.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	872	872	C	137	C,T	124,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1390	17.3	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1231	1233	AAT	5;4;4	A;A;T	5;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1390	17.3	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1234	1236	AAT	4;4;4	A;A;T	4;3;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1390	17.3	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1246	1248	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1390	17.3	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1258	1260	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1390	17.3	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1281	1283	GTA	2;2;2	G;T;A	1;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	80	porB1a	984	184	90.96	porB1a.l15.c4.ctg.1	1390	17.3	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1290	1290	A	2	A	2	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	G38E	NONSYN	112	114	GGA	476	478	GAA	165;166;166	G;A;A	143;146;144	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	S46G	NONSYN	136	138	AGC	500	502	GGC	169;170;170	G;G;C	149;150;148	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	506	508	GGA	168;167;166	G;G;A	150;145;143	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	T87A	NONSYN	259	261	ACT	623	625	GCT	168;167;166	G;C;T	152;150;150	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	T89S	NONSYN	265	267	ACC	629	631	AGC	167;165;165	A,C;G;C	148,1;149;149	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	.	MULTIPLE	358	359	AA	721	722	CG	173;172	C,G;G	158,1;159	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	.	MULTIPLE	361	362	GA	724	726	CAG	171;171;170	C;A;G,T	160;157;160,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	N122K	NONSYN	364	366	AAC	728	730	AAA	168;166;163	A;A;A	156;156;153	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	K143E	NONSYN	427	429	AAA	791	793	GAA	159;158;158	G,A;A;A	146,1;140;145	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	V151A	NONSYN	451	453	GTA	815	817	GCA	160;160;160	G;C,A;A	142;142,1;143	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	923	925	CGA	141;141;141	C;G;A	134;133;132	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1007	1009	ACT	120;120;121	A;C;T	111;111;107	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1010	1012	CAT	121;121;120	C;A;T	109;107;109	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1016	1018	ATG	123;123;124	A;T;G	112;113;115	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	.	MULTIPLE	766	767	AC	1130	1132	GCA	102;102;103	G;C,A;A	97;96,1;94	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	W257R	NONSYN	769	771	TGG	1134	1136	CGG	102;102;102	C;G;G	97;97;95	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	0	.	p	.	0	S258fs	FSHIFT	772	772	A	1137	1137	A	102	A	97	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	1	SNP	p	G120K	1	.	.	358	360	AAG	721	723	CGG	173;172;172	C,G;G;G	158,1;159;162	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	1	SNP	p	D121N	0	.	.	361	363	GAC	724	727	CGC	171;170;168	C;G,T;C	160;160,1;156	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	744	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1746	124.1	1	SNP	p	A121D	1	.	.	361	363	GAC	724	727	CGC	171;170;168	C;G,T;C	160;160,1;156	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1786	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	5347	99.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2271	2273	AAT	110;109;109	A;A;T	98;99;96	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	162	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1376	35.1	1	SNP	p	V57M	1	.	.	169	171	ATG	697	699	ATG	61;61;61	A;T;G	57;58;54	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
